Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment.
Khary EdwardsAleksandra UruskaAnna Duda-SobczakDorota Zozulinska-ZiolkiewiczIldiko LingvayPublished in: Therapeutic advances in endocrinology and metabolism (2023)
Patients with T1DM report initiating adjuvant treatment with GLP-1RA and/or SGLT2i to improve glycemic control and lose weight; most patients reported perceived benefits from these therapies. Side effects (including DKA) are reported more commonly in real life than in clinical trials. Given patient interest in these medications, further studies should evaluate the long-term risk-benefits ratio in larger cohorts.
Keyphrases
- glycemic control
- type diabetes
- physical activity
- clinical trial
- end stage renal disease
- weight loss
- blood glucose
- social support
- depressive symptoms
- case report
- chronic kidney disease
- mental health
- newly diagnosed
- ejection fraction
- early stage
- rheumatoid arthritis
- cardiovascular disease
- systematic review
- peritoneal dialysis
- randomized controlled trial
- open label
- skeletal muscle
- disease activity
- patient reported outcomes
- systemic lupus erythematosus
- body weight
- ankylosing spondylitis
- risk assessment
- human health
- idiopathic pulmonary fibrosis
- interstitial lung disease